HomeCompareAZEK vs PFE

AZEK vs PFE: Dividend Comparison 2026

AZEK yields 3.68% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $24.2K in total portfolio value· pulled ahead in Year 9
10 years
AZEK
AZEK
● Live price
3.68%
Share price
$54.35
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$466.18
Full AZEK calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AZEK vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAZEKPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AZEK + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AZEK pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AZEK
Annual income on $10K today (after 15% tax)
$312.79/yr
After 10yr DRIP, annual income (after tax)
$396.25/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,923.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AZEK + PFE for your $10,000?

AZEK: 50%PFE: 50%
100% PFE50/50100% AZEK
Portfolio after 10yr
$37.5K
Annual income
$13,362.45/yr
Blended yield
35.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AZEK
Analyst Ratings
13
Buy
12
Hold
Consensus: Buy
Price Target
$40.92
-24.7% upside vs current
Range: $16.00 — $58.00
Altman Z
6.8
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AZEK buys
5
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Michael McCaul🏢 House$AZEK▼ Sell$15,001 - $50,0002023-01-13
Michael McCaul🏢 House$AZEK▼ Sell$15,001 - $50,0002023-01-13
Susie Lee🏢 House$AZEK▼ Sell$1,001 - $15,0002022-11-30
Michael McCaul🏢 House$AZEK▲ Buy$15,001 - $50,0002022-09-01
Michael McCaul🏢 House$AZEK▲ Buy$15,001 - $50,0002022-09-01
Susie Lee🏢 House$AZEK▲ Buy$1,001 - $15,0002021-01-28
Susie Lee🏢 House$AZEK▲ Buy$1,001 - $15,0002021-01-22
Susie Lee🏢 House$AZEK▲ Buy$1,001 - $15,0002020-12-16
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAZEKPFE
Forward yield3.68%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$25.4K$49.6K
Annual income after 10y$466.18$26,258.71
Total dividends collected$4.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$40.92$27.50

Year-by-year: AZEK vs PFE ($10,000, DRIP)

YearAZEK PortfolioAZEK Income/yrPFE PortfolioPFE Income/yrGap
1$11,068$367.99$9,153$693.39+$1.9KAZEK
2$12,223$380.64$8,593$849.25+$3.6KAZEK
3$13,472$392.87$8,336$1,066.78+$5.1KAZEK
4$14,820$404.68$8,437$1,384.80+$6.4KAZEK
5$16,273$416.04$9,013$1,875.40+$7.3KAZEK
6$17,839$426.95$10,306$2,680.72+$7.5KAZEK
7$19,525$437.42$12,820$4,101.38+$6.7KAZEK
8$21,339$447.45$17,673$6,826.70+$3.7KAZEK
9← crossover$23,290$457.03$27,543$12,591.86$4.3KPFE
10$25,387$466.18$49,560$26,258.71$24.2KPFE

AZEK vs PFE: Complete Analysis 2026

AZEKStock

The AZEK Company Inc. engages in designing, manufacturing, and selling building products for residential, commercial, and industrial markets in the United States. It operates through two segments: Residential and Commercial. The Residential segment designs and manufactures engineered outdoor living products, which includes decking, railing, trim and moulding, and accessories under the TimberTech, AZEK Exteriors, VERSATEX, and ULTRALOX brand name. Its Commercial segment manufactures engineered polymer materials that is used in various industries, which includes outdoor, graphic displays and signage, educational, and recreational markets, as well as the food processing and chemical industries. This segment also offers bathroom partitions, shower and dressing stalls, lockers, and other storage solutions under the Aria, Eclipse, Hiny Hiders, TuffTec, and Duralife brand name to schools, parks, stadium arenas, industrial plants, and retail, recreational, and commercial facilities. The company was formerly known as CPG Newco LLC and changed its name to The AZEK Company Inc. in June 2020. The AZEK Company Inc. was incorporated in 2013 and is headquartered in Chicago, Illinois.

Full AZEK Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AZEK vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AZEK vs SCHDAZEK vs JEPIAZEK vs OAZEK vs KOAZEK vs MAINAZEK vs JNJAZEK vs MRKAZEK vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.